Nabriva Therapeutics plc
Nabriva Therapeutics plc (NBRV) Stock Overview
Explore Nabriva Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
4.5M
P/E Ratio
-0.07
EPS (TTM)
$-19.67
ROE
-2.02%
NBRV Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Nabriva Therapeutics plc (NBRV) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.31.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.07 and a market capitalization of 4.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.